Position statement: immunomodulator therapy for inflammatory Bowel disease

Isr Med Assoc J. 2003 Mar;5(3):164-9.

Authors

Alexandra Lavy¹, Yehuda Chowers, H Shmuel Odes, Rami Eliakim; Israel gastroenterology association

Affiliation

¹ Department of Gastroenterology, Bnei Zion Medical Center and Technion Faculty of Medicine, Haifa, Israel.

PMID: 12725133

No abstract available

Publication types

Guideline
Practice Guideline

MeSH terms

Adjuvants, Immunologic / adverse effects
Adjuvants, Immunologic / therapeutic use*
Azathioprine / adverse effects
Azathioprine / therapeutic use
Clinical Trials as Topic
Contraindications
Cyclosporine / adverse effects
Cyclosporine / therapeutic use
Humans
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use*
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / immunology
Mercaptopurine / adverse effects
Mercaptopurine / therapeutic use
Methotrexate / adverse effects
Methotrexate / therapeutic use
Safety
Tumor Necrosis Factor-alpha / adverse effects
Tumor Necrosis Factor-alpha / therapeutic use

Substances

Adjuvants, Immunologic
Immunosuppressive Agents
Tumor Necrosis Factor-alpha
Cyclosporine
Mercaptopurine
Azathioprine
Methotrexate